Document:

ex101.htm

EXHIBIT 10.1

 

 

 SHARE PURCHASE AGREEMENT

 

This Share Purchase Agreement (the “Agreement”) is dated as of May 13, 2012 between BioCancell Therapeutics Inc., a corporation incorporated under the laws of the state of Delaware (the “Company”), and Clal Biotechnology Industries Ltd., a corporation incorporated under the laws of the State of Israel ("CBI").

 

WHEREAS, the Company received loans (the "Loans"), which are convertible into Common Stock (as such term is defined below), from each of CBI, Tikcro Technologies Ltd. ("Tikcro") and the Provident Fund of the Employees of the Hebrew University Ltd. (the "Provident Fund"); and

 

WHEREAS, the repayment date of the Loans is July 30, 2012 (the "Repayment Date"); and

 

WHEREAS, CBI, subject to the terms herein, and the Provident Fund have each informed the Company that they are willing to convert their respective Loans, in full, into Common Stock (as such term is defined below); and

 

WHEREAS, Tikcro, as of the date hereof, has not informed the Company of its intention to convert its Loan into Common Stock, and pursuant to the terms of such Loan, should it not be converted, the Loan must be repaid on the Repayment Date; and

 

WHEREAS, the Company wishes to ensure that the Tikcro Loan (as such term is defined below) shall be repaid on the Repayment Date; and

 

WHEREAS, CBI is willing to invest in the Company, in consideration for Common Stock (as such term is defined below), an amount equivalent to the Tikcro Loan (as such term is defined below) for the purpose of enabling the Company to repay the Tikcro Loan in full;

 

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and CBI agree as follows:

 

	
  

	
1.

	
Definitions.

 

In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings indicated in this Section 1:

 

“Board” means the Board of Directors of the Company.

 

“Business Day” means any day except days on which banking institutions in the State of Israel are authorized or required by law or other governmental action to close.

 

“CBI Loan” means the outstanding amount of principal plus incurred interest, as of 11:59pm on July 30, 2012 (not including amounts that were converted into Common Stock prior to or at such time) under the Unsecured Convertible Promissory Note,  between CBI and the Company, dated July 30, 2008.

 

“Common Stock” means (i) prior to the consummation of the Reorganization, the common stock of the Company, par value USD$0.01 per share and (ii) subsequent to the consummation of the Reorganization, ordinary shares of BioCancell Ltd., each having a nominal value of NIS0.01.

 

  

  

  

“Companies Law” means the Israeli Companies Law, 5759 – 1999, as amended and the rules and regulations promulgated thereunder.

 

“ISA” means the Israel Securities Authority.

 

“Price Per Share” means NIS0.87 which was calculated as the average closing price of a share of Common Stock during the sixty (60) Trading Days prior to April 24, 2012 (the date on which the Board approved the Investment (as such term is defined below)).

 

“Provident Fund Loan” means the outstanding amount of principal plus incurred interest, as of 11:59pm on July 30, 2012 (not including amounts that were converted into Common Stock prior to or at such time) under the unsecured convertible promissory note between Provident Fund and the Company, dated July 30, 2008.

 

“Reorganization” means the contemplated reorganization of the Company (which was reported on the TASE website on November 6, 2011) through a reverse triangular merger pursuant to which holders of securities of the Company will receive securities (at a 1:1 exchange ratio) with similar terms of BioCancell Ltd. in lieu of their securities of the Company, and the Provident Fund Loan, Tikcro Loan and CBI Loan will be assigned to BioCancell Ltd. (which will assume all of the obligations of the Loans in accordance with their terms). Shareholders of the Company shall receive one ordinary share of BioCancell Ltd., each having a nominal value of NIS0.01, in consideration of each share of Common Stock held in the Company (i.e. 1:1 exchange ratio)

 

“Securities Law” means the Israeli Securities Law, 5728 - 1968.

 

“Tikcro Loan” means the outstanding amount (after taking into account any partial conversion of such loan into Common Stock) of principal plus incurred interest, as of 11:59pm on July 30, 2012, under the unsecured convertible promissory note between Tikcro and the Company, dated July 30, 2008. For the avoidance of doubt, the amount of the Tikcro Loan shall be USD$2,480,500 subject to any amounts converted into Common Stock prior to or at that time.

 

“TASE” means the Tel-Aviv Stock Exchange Ltd.

 

“Trading Day” means a day on which the Common Stock is permitted to be traded on the TASE.

 

	
  

	
2.

	
The Investment.

 

	
  

	
2.1.

	
The Company shall promptly (within one Trading Day) inform CBI in writing should Tikcro  ask to convert part or all of the Tikcro Loan into Common Stock, provide CBI with the updated balance of the Tikcro Loan following such conversion and shall promptly provide CBI with any documentation or information reasonable requested by CBI in connection with such conversion.

 

	
  

	
2.2.

	
The Company shall (i) inform CBI, in writing no later than July 29, 2012 at 12:00PM (Israel Time) of the details of Tikcro's bank account (the “Account Details”) and (ii) confirm to CBI, in writing no later than July 31, 2012 at 9:00AM (Israel Time) that no additional conversion was requested by Tikcro or made (other than those reported in accordance with section 2.1 above) and the exact balance of the Tikcro Loan (the "Notice").

 

  

  

  

	
  

	
2.3.

	
Subject to timely receipt of the Account Details and Notice pursuant to Section 2.1 above, and provided that the Provident Fund agrees to convert the Provident Fund Loan in full, if Tikcro does not convert the Tikcro Loan in full, CBI shall transfer directly to Tikcro's bank account, by July 31, 2012 no later than 12:00PM (Israel Time) (the “Closing Time”), an amount equal to the Tikcro Loan, as detailed in the Notice (the "Investment" and the "Investment Amount", respectively).

 

	
  

	
2.4.

	
Promptly upon receiving proof, to the full satisfaction of the Company, of deposit of the Investment Amount in Tikcro's bank account from CBI, and in consideration for the Investment, the Company will issue a share certificate to CBI, bearing the restrictive legend set forth in Section 4 below, representing the number of Common Stock determined by dividing the Investment Amount (converted to New Israeli Shekels based on the Bank of Israel representative exchange rate on April 23, 2012 – NIS 3.764 per USD$1) by the Price Per Share (the "Shares"). For the avoidance of doubt, if the amount of the Tikcro Loan shall be USD$2,480,500, the amount of Shares issued shall be 10,731,726.

 

	
  

	
2.5.

	
CBI agrees and acknowledges that subject to the issuance of the Shares as described in section 2.4 above, as of December 31, 2012.

 

	
  

	
2.5.1.

	
Section 8 of the Subscription and Registration Rights Agreement, dated June 22, 2008, between CBI and the Company, will no longer be in force and effect.

 

	
  

	
2.5.2.

	
Sections 2.6 through 2.10 of the Unsecured Convertible Promissory Note, dated July 30, 2008, between CBI and the Company, will no longer be in force and effect.

 

	
  

	
2.5.3.

	
Section 3.7 of the Assignable Warrant, dated July 30, 2008, between CBI and the Company, will no longer be in force and effect.

 

	
  

	
2.6.

	
CBI and the Company each acknowledge that if Tikcro chooses to convert the Tikcro Loan, in full, into Common Stock, then this Agreement shall be null and void (including Section 2.5 above but excluding Section 3.1 below), CBI will not make the Investment and accordingly the Company will not issue any Common Stock to CBI and CBI and the Company shall have no claim or demand against each other in connection with the contemplated Investment.

 

	
  

	
2.7.

	
The execution of this Agreement and the Investment is subject to the satisfaction of the conditions precedent detailed in section 6 below.

 

	
  

	
3.

	
Representations and Warranties of CBI

 

CBI hereby represents and warrants to the Company as follows:

 

	
  

	
3.1.

	
Conversion of CBI Loan. CBI agrees to convert the CBI Loan, in full, into Common Stock, in accordance with the provisions of the Unsecured Convertible Promissory Note, dated July 30, 2008, between CBI and the Company provided that the Provident Fund convert, in full, the Provident Fund Loan as per Section 6.1.1 below. For the avoidance of doubt, it is made clear, that subject to the satisfaction of the conditions precedent in Section 6 below, CBI's irrevocable undertaking to

 

  

  

  

	
  

	
convert the CBI Loan, in full, into Common Stock is regardless of whether or not Tikcro will convert the Tikcro Loan.

 

	
  

	
3.2.

	
Corporate Authorization; Validity of Proposal. CBI has the full corporate power and authority to execute this Agreement. The execution, delivery and performance of this Agreement by CBI have been duly authorized by all requisite corporate actions and no further consent or authorization of CBI, its directors and/or shareholders is required. This Agreement has been duly authorized, executed and delivered by CBI and, when duly authorized, executed and delivered by the Company, will form a valid and binding agreement enforceable against CBI in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and other similar laws of general applicability relating to or affecting creditors’ rights generally and to general principles of equity.

 

	
  

	
3.3.

	
CBI Status. CBI hereby declares that it: (i) is not an investor of the type listed in the First Schedule of the Israeli Securities Law; and (ii) is, and at the time of the issuance of the Shares to it will be, an "accredited investor" as that term is defined in Rule 501(a)(3) of Regulation D promulgated under the Securities Act of 1933 (the “Securities Act”).

 

	
  

	
3.4.

	
Reliance on Exemptions.  CBI understands that the Shares are being issued and sold to it without registration under the Securities Act in a private placement that is exempt from the registration provisions of the Securities Act, and that the Company is relying in part upon the truth and accuracy of CBI's representations and warranties set forth herein in order to determine the availability of such exemptions and the eligibility of CBI to make the Investment in consideration for the Shares.

 

	
  

	
3.5.

	
Investment Purpose; No Affiliation with Other Investors; No Controlling Interest.  CBI is purchasing the Shares for its own account and not in conjunction with any other party purchasing the Shares under the terms and conditions hereof. CBI is purchasing for investment purposes only and not with a view to, or for resale in connection with, the public sale or distribution thereof, except pursuant to resales registered under the Securities Act and in compliance with applicable state securities laws or under an exemption therefrom. There are no agreements between CBI and any other party with respect to the purchase or sale of securities of the Company or with respect to the voting rights in the Company.

 

	
  

	
3.6.

	
Knowledge and Experience. CBI has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment in the Company, has evaluated the merits and risks of such investment, accepts the terms and conditions of such investment, has the ability to bear the economic risks of its investment for an indefinite period of time, can afford the complete loss of its investment and recognizes that an investment in the Company involves substantial risk.

 

	
  

	
3.7.

	
Access to Information. CBI acknowledges that the Company files reports regarding material aspects of its activity in accordance with the Israeli Securities Law and the regulations promulgated there under and that the reports are available to CBI.

 

  

  

  

	
  

	
CBI also acknowledges that it has been afforded the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the Reorganization and the terms and conditions of the offering and the merits and risks of investing in the Company's Common Stock.

 

	
  

	
3.8.

	
Transfer or Resale. CBI understands and acknowledges that (i) the Shares are restricted for resale through the TASE in accordance with the Israeli Securities Law and the relevant regulations related to such restrictions on resale, for the periods and amounts specified therein; and (ii) the Shares have not been registered under the Securities Act and may not be offered or sold in the U.S. unless the Shares are registered under the Securities Act or the Company receives  an opinion of legal counsel reasonably satisfactory to the Company that such registration is not required under the Securities Act.

 

Unless so registered (or exempt from registration) the Shares: (a) will be issued by way of a physical share certificate (and not electronically) that will bear a restrictive legend as specified in section 4 below; (b) will only be registered in the register of shareholders of the Company; (c) shall not be registered for trade on the TASE (or any other stock exchange or trading system); and (d) may not be offered for sale, sold, assigned or transferred.

 

	
  

	
3.9.

	
General Solicitation. CBI is not purchasing the Shares to be acquired by it as a result of, and CBI is not aware of, any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar relating to the sale of the Shares.

 

	
3.10.

	
No Other Representations and Warranties. Except for the representations and warranties expressly and specifically made by the Company in this Agreement, the Company does not make any express or implied representation or warranty, and the Company hereby disclaims all other representations and warranties of any kind or nature, express or implied.

 

	
  

	
4.

	
No Registration

 

CBI acknowledges that until the sale of the Shares under an effective registration statement under the Securities Act or until the earlier receipt by the Company of an opinion of legal counsel reasonably satisfactory to the Company that such registration is not required under the Securities Act, the share certificates or other instruments representing the Shares shall bear a restrictive legend composed of exactly the following words capitalized below:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE

 

  

  

  

SECURITIES ACT OF 1933, AS AMENDED, OR (2) AN OPINION OF HOLDER’S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS.

 

The legend may be revised, at any time (provided prompt notice is provided to CBI of such revision), to the extent required by applicable securities laws or contract.

 

The Company undertakes to use its commercially reasonable efforts to assist CBI in registering the securities for trade on the TASE, upon and subject to receipt from CBI of an opinion of legal counsel satisfactory to the Company, that the above restrictive legend may be removed. At the request of CBI, the Company will coordinate the receipt of such counsel opinion and the cost of such opinion shall be born by the Company.

 

	
  

	
5.

	
Representations and Warranties of the Company

 

The Company hereby represents and warrants to CBI as follows:

 

	
  

	
5.1.

	
Organization.  The Company has been duly incorporated, is validly existing and in good standing under the laws of Delaware.

 

	
  

	
5.2.

	
Corporate Authorization; Execution; Validity of Proposal.  The Company has the full corporate power and authority to execute  this Agreement and each of the other agreements, certificates or other instruments required to be delivered hereunder by the Company (the "Transaction Documents"), including the sale, issuance and delivery of the Shares. The execution, delivery and performance of this Agreement by the Company have been duly authorized by all requisite corporate actions and no other authorizations, consents or corporate proceedings on the part of  the Company, the Board or the Company’s shareholders shall be necessary to authorize this Agreement or to consummate the transactions contemplated hereby and thereby, except for the conditions precedent listed in Section 6 hereof, which shall be completed prior to the Closing Time:

 

Subject to meeting the conditions precedent per Section 6 below, the Transaction Documents will be duly authorized, executed and delivered by the Company and, when duly authorized, executed and delivered by CBI, will be valid and binding agreements enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and other similar laws of general applicability relating to or affecting creditors’ rights generally and to general principles of equity.

 

	
  

	
5.3.

	
Corporate Authority.  The Company has full corporate power and authority necessary to (i) perform its obligations hereunder (subject to meeting the above mentioned conditions precedent); and (ii) carry on its business as presently proposed to be conducted.

 

	
  

	
5.4.

	
Validity of Common Stock.  When issued to CBI against full payment therefore, all applicable Shares will have been duly and validly issued, fully paid and non-assessable; shall not be subject to call or forfeiture rights and will be free and clear of any security interests, liens, claims, encumbrances or other third party interests, other than those restrictions contemplated by the federal and state securities laws of the

 

  

  

  

	
  

	
United States and the securities laws and regulations of Israel; and will not have been issued or sold in violation of any preemptive or other similar rights of the holders of any securities of the Company.

 

	
  

	
5.5.

	
No Conflicts; Compliance.  The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the Company’s Articles of Incorporation or By-laws or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, or instrument to which the Company is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal, state and foreign securities laws and regulations applicable to the Company or by which any property or asset of the Company is bound or affected).

 

	
  

	
5.6.

	
Accuracy of Public Disclosures. All of the information included in the Company's Israeli 2011 Annual Report that was published on the TASE website on February 23, 2012, was accurate in all material respects as of the date of its publication. Following the date of the 2011 Annual Report, any material information which was required to be disclosed to the public under Israeli law, has been disclosed by the Company through the website of the TASE at http://www.tase.co.il/TASE/Homepage.htm in accordance with applicable law.

 

	
  

	
5.7.

	
SEC Documents; Financial Statements. The Company has filed all reports and other documents required to be filed by the Company under the Securities Act and Exchange Act of 1934, as amended (the “Exchange Act”) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Documents”) on a timely basis. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable. The financial statements of the Company included in the SEC Documents comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. To the Company’s knowledge, the SEC has not commenced any enforcement proceedings against the Company.

 

	
  

	
5.8.

	
Adjustment due to future issuance of Company's Shares. In any event that during the Adjustment Period (as defined below) the Company issues any additional Common Stock or convertible securities (including convertible debt, options and warrants) to any third party or CBI, save for Excluded Issuances (as defined below) ("Future Issuance"), either at an Average Share Price (as defined below), exercise price or conversion price per share which is less than NIS0.87, adjusted, according to TASE rules, to any dividend, split or any capital restructuring during the Adjustment Period, then the Company shall promptly and subject to obtaining all the required approvals (including but not limited to, the approval of the TASE), issue to CBI a number of additional shares of Common Stock that is equal to the difference between the number of Shares issued to CBI in accordance with this Agreement and the number of shares of Common Stock that would have been issued to CBI at a price

 

  

  

  

	
  

	
per share which is equal to the Average Share Price, exercise price or conversion price, as applicable.

 

"Excluded Issuances" shall mean any of the following: (i) securities issued to directors, officers, employees and or consultants of the Company or any other company controlled by the Company ("Controlled Company"), pursuant to any stock option or stock incentive plan reserved for Company's and/or Controlled Company's officers,  directors, employees or consultants and approved by the Company's Board , and, if applicable, any securities issued upon the exercise of such securities; (ii) securities issued pursuant to any stock split, recapitalization, reclassification or payment of any dividend or distribution with respect to the Company's issued and outstanding share capital, including any bonus shares; (iii) securities issued upon the conversion of any convertible securities including exercise of options and/or warrants and conversion of a convertible debenture; (iv) securities issued in connection with an acquisition transaction of another entity in the field of business of the Company as approved by the Board which issuance shall not exceed 30% of the Company’s issued and outstanding Common Stock as of the date hereof; or (v) securities issued in connection with the Company's contemplated Reorganization; (vi) the next fund raising round by the Company if only CBI will participate in such fund raising round and the latter invests an amount which is less than USD$1,000,000.

 

"Adjustment Period" shall mean the period commencing on the date hereof (subject to the execution of this Agreement and the actual issuance of the Shares as described in Section 2.4 above) and ending on December 31 2012.

 

"Average Share Price" shall mean the lower of: (i) the average closing price of Common Stock during the 22 Trading Days prior to the date on which the Board approved such Future Issuance; or (ii) the purchase price per Common Stock at the Future Issuance.

 

	
  

	
6.

	
Conditions Precedent

	
  

	
6.1.

	
The obligations of CBI under this Agreement are subject to the satisfaction of each of the following conditions on or prior to the Closing Time:

 

	
  

	
6.1.1.

	
Provident Fund shall have given the Company an irrevocable written notice of its election to convert the Provident Fund Loan (in full) to Common Stock (which may be subject only to the conversion by CBI of the CBI Loan and the shareholder approval described in Section 6.1.3 below) prior to, or concurrently with, the Investment (such notice to be promptly provided to CBI upon receipt) and shall convert the Provident Fund Loan (in full) to Common Stock on or prior to the Closing Time;

 

	
  

	
6.1.2.

	
The representations and warranties of the Company shall be true and correct in all material respects as of the date hereof and as of the Closing Time as though made at that time, and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Closing Time;

 

  

  

  

	
  

	
6.1.3.

	
The approval at a general meeting of the Company's shareholders of the Investment in accordance with Section 270(4) and Section 328(b)(3) of the Companies Law;

 

	
  

	
6.1.4.

	
The approval of the TASE for listing the Shares to trade; and

 

	
  

	
6.1.5.

	
Receipt by the Company and CBI, to the extent required under law, of an approval of, or exemption from, the Israeli Restrictive Trade Practices Authority, for the purchase of the Shares, in a form acceptable to both the Company and CBI.

 

	
  

	
6.2.

	
The obligations of the Company under this Agreement are subject to the satisfaction of each of the following conditions on or prior to the Closing Time:

 

	
  

	
6.2.1.

	
Sections 6.1.3, 6.1.4 and 6.1.5 above;

 

	
  

	
6.2.2.

	
The representations and warranties of CBI shall be true and correct in all material respects as of the date hereof and as of the Closing Time as though made at that time, and CBI shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by CBI at or prior to the Closing Time;

 

	
  

	
7.

	
Miscellaneous

	
  

	
7.1.

	
Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the state of Israel, without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdictions other than the State of Israel. Each party hereby irrevocably submits to the exclusive jurisdiction of the courts of Tel Aviv-Jaffa. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.

 

	
  

	
7.2.

	
Counterparts.  This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature delivered by e-mail in a “.pdf” format data file shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.

 

	
  

	
7.3.

	
Headings.  The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

 

	
  

	
7.4.

	
Entire Agreement.  The Transaction Documents supersede all other prior oral or written agreements between CBI, the Company, their affiliates and persons acting on their behalf with respect to the subject matter thereof, and this Agreement, the other Transaction Documents and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor CBI makes any representation, warranty, covenant or undertaking with respect to such

 

  

  

  

	
  

	
matters.  The Company acknowledges and agrees that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly set forth in the Transaction Documents.

 

	
  

	
7.5.

	
Notices.  Any notices, consents or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt when delivered personally; or (ii) one day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses for such communications shall be:

 

  

  

  

If to the Company:

BioCancell Therapeutics Inc.

8 Hartom St.

Jerusalem 97775, Israel

Tel.: +972-2-548-6555 Fax: +972-2-548-6550

Attn: Jonathan Burgin, Chief Financial Officer

With copies to (which shall not constitute notice or service of process):

 

Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co

1 Azrieli Center (Round Building)

Tel Aviv 67021, Israel

Tel.:  972-3-607-4441+   Fax:  972-3-691-4177+

Attn: Dr.  Shachar Hadar, Adv. Sarit Leviathan

 

And if to CBI:

 

Clal Biotechnology Industries Ltd.

Hogi Tower

12 Abba Hillel Silver St.

Ramat Gan 52506, Israel

Tel.: +972-3-612-1616

Attn: Adv. Orit Lidor, Adv. Yaron Meyer

With copies to (which shall not constitute notice or service of process):

 

Yigal Arnon & Co.

1 Azrieli Center (Round Building)

Tel Aviv 67021, Israel

Tel.: +972-3-608-7871

Attn: Gil Oren

or at such other address and/or to the attention of such other person as the recipient party has specified by written notice given to the other party three (3) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent or other communication or (B) provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service or receipt from a nationally recognized overnight delivery service in accordance with clause (i) or (ii) above, respectively.

 

	
  

	
7.6.

	
Successors and Assigns.

 

	
  

	
7.6.1.

	
This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns.

 

	
  

	
7.6.2.

	
Except as provided in this Section 7.6.2 and in Section 7.6.3 below, no party shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party, including by merger or consolidation.

 

The obligations and rights of CBI may be assigned by CBI prior to date of the  shareholder meeting scheduled in order to approve the Investment, as per Section 6.1.3 above,  in whole or in part, subject to the satisfaction of all the following conditions: (i) CBI has notified the Company of such an

  

  

  

assignment, in writing, no later than 10 days prior to the date of the general meeting of shareholders of the Company scheduled in order to approve the Investment ("Notice of Assignment"); (ii) such Notice of Assignment shall include all details reasonable requested by the Company with respect to the assignee and the assignment; and (iii) promptly upon the request of the Company, CBI shall provide the Company with any additional information in connection with the assignment, as the Company may reasonably require, inter alia, in order to enable the Company to amend the immediate report with respect to the general meeting of shareholders. Following the issuance of the Shares to CBI by the Company, CBI may assign its rights and obligations under this Agreement to any person that acquires any, or all of, the Shares from CBI. For the avoidance of doubt, any assignee of CBI (not including a person/entity that purchased part or all the Shares from CBI), other than an entity controlled (as the term "Control" is defined under the Securities Law), directly or indirectly (including together with others) by CBI, shall be considered a “third party” for purposes of Section 7(f) of the Proposal Form between the parties hereto, entered into on December 6, 2011.

The obligations and rights of CBI may also be assigned by CBI after obtaining the shareholder meeting approval to the Investment (as per Section 6.1.3 above) and prior to the actual issuance of the Shares to CBI, subject to obtaining all the required approvals to such an assignment, to the full satisfaction of the Company.

	
  

	
7.6.3.

	
CBI acknowledges and agrees, and the Company and BioCancell Ltd. each agree, that in the event the Reorganization is consummated prior to July 31, 2012, BioCancell Ltd. shall assume the obligations of the Company under this Agreement and shall be deemed to have made the same representations and warranties as the Company under this Agreement (except that “Delaware” shall be replaced with “Israel” for purpose of Section 5.1), mutatis mutandis, and CBI shall be granted in lieu of each share of Common Stock issuable to CBI under this Agreement, one ordinary share of BioCancell Ltd. CBI shall have no claim or demand against the Company, BioCancell Ltd. and their respective directors and officers in connection with assumption of the Company's obligations under this Agreement by BioCancell Ltd.

 

	
  

	
7.7.

	
No Third Party Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

	
  

	
7.8.

	
Further Assurances.  Each party shall do and perform, or cause to be done and performed, all such further reasonable acts and things, and shall execute and deliver all such other reasonable agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement.

 

	
  

	
7.9.

	
No Strict Construction.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

 

  

  

  

	
7.10.

	
Failure or Indulgence Not Waiver.  No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege.

 

 

(Signature Page Follows)

 

 

 

 

	
CLAL BIOTECHNOLOGY INDUSTRIES LTD.

	  	
BIOCANCELL THERAPEUTICS INC.

	
By: /s/ Gil Milner

      Name: Gil Milner

 Title: CFO

	  	
By: /s/ Uri Danon

      Name: Uri Danon

 Title: CEO

	
By: /s/ Tamar Manor

      Name: Tamar Manor

 Title: Director

	  	
By: /s/ Jonathan Burgin 

      Name: Jonathan Burgin

 Title: Chief Financial Officer

 

 

 

 

 

	
BIOCANCELL LTD.

	
By: /s/ Uri Danon

      Name: Uri Danon

 Title: CEO

	
By: /s/ Jonathan Burgin

      Name: Jonathan Burgin

 Title: Chief Financial OfficerEXHIBIT 4.1 SUBSCRIPTION AGREEMENT

 

 

 Exhibit 4.1
 

 SUBSCRIPTION AGREEMENT
 

 

 THIS SUBSCRIPTION AGREEMENT made as of this _____ day of _______ 2012 between 
  KOFFEE KORNER INC., a corporation organized under the laws of the State of Delaware with offices c/o Nazneen D’Silva 6560 Fannin Street, Suite 245, Houston, TX 77030 (the “Company”), and the undersigned (the “Subscriber” and together with each of the other subscribers in the Offering (defined below), the “Subscribers”).
 WHEREAS, the Company desires to issue up to $100,000 (100 Units) aggregate amount of units (a “Unit” and collectively, the “Units”) in a private placement (the “Offering”), at a purchase price of $1,000 per Unit;
 WHEREAS, each Unit shall consist of ten thousand (10,000) shares of Common Stock, par value $.0001 per share (the “Shares”); and
 WHEREAS, the Subscriber is delivering simultaneously herewith a completed confidential investor questionnaire (the “Questionnaire”),
 NOW, THEREFORE, for and in consideration of the promises and the mutual covenants hereinafter set forth, the parties hereto do hereby agree as follows:
 I.
 SUBSCRIPTION FOR UNITS AND REPRESENTATIONS BY AND COVENANTS OF SUBSCRIBER
 1.1.
 Subscription for Units. Subject to the terms and conditions hereinafter set forth, the Subscriber hereby subscribes for and agrees to purchase from the Company such aggregate amount of Units as is set forth upon the signature page hereof; and the Company agrees to sell such Units to the Subscriber for said purchase price subject to the Company’s right to sell to the Subscriber such lesser number of Units as the Company may, in its sole discretion, deem necessary or desirable. The purchase price is payable by certified or bank checks made payable to “Koffee Korner Inc.” and delivered contemporaneously with the execution and delivery of this Subscription Agreement to the Company’s address set forth above. 
 1.2.
 Reliance on Exemptions. The Subscriber acknowledges that this Offering has not been reviewed by the United States Securities and Exchange Commission (“SEC”) or any state agency because of the Company’s representations that this is intended to be a nonpublic offering exempt from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and state securities laws. The Subscriber understands that the Company is relying in part upon the truth and accuracy of, and the Subscriber’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Subscriber set forth herein in order to 
 

 

 

 
 

 

 determine the availability of such exemptions and the eligibility of the Subscriber to acquire the Units.
 1.3.
 Investment Purpose. The Subscriber represents that the Shares comprising the Units (the “Securities”) are being purchased for his or her own account, for investment purposes only and not for distribution or resale to others in contravention of the registration requirements of the 1933 Act. The Subscriber agrees that it will not 
 sell or otherwise transfer the Securities unless they are registered under the 1933 Act or unless an exemption from such registration is available.
 1.4.
 Accredited Investor. The Subscriber represents and warrants that he or she is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the 1933 Act, as indicated by its responses to the Questionnaire, and that it is able to bear the economic risk of any investment in the Units. The Subscriber further represents and warrants that the information furnished in the Questionnaire is accurate and complete in all material respects.
 1.5.
 RISK OF INVESTMENT. THE SUBSCRIBER RECOGNIZES THAT THE PURCHASE OF THE UNITS INVOLVES A HIGH DEGREE OF RISK INCLUDING, WITHOUT LIMITATION, ANY AND ALL RISKS DISCUSSED IN THIS SUBSCRIPTION AGREEMENT.  AN INVESTMENT IN THE COMPANY AND THE UNITS MAY RESULT IN THE LOSS OF A SUBSCRIBER’S ENTIRE INVESTMENT.
 (a)
 Risk of Loss of Investment.  An investment in the Company and the Units offered hereby involve a high degree of risk.  An investment in the Units is suitable only for investors who can bear a loss of their entire investment.
 (b)
 Value of Shares is Speculative.  The terms of this offering have been determined arbitrarily by the Company.  There is no relationship between such terms and the Company’s assets, earnings, book value and/or any other objective criteria of value.
 (c)
 Dependence on Net Proceeds; No Minimum Offering.  The Company is wholly dependent upon the net proceeds of this Offering to fund its operations, as more specifically described elsewhere in this Subscription Agreement. There is no commitment by any person to purchase Units and there is no assurance that any number of Units will be sold.  Additionally, there is no minimum amount of funds that are required to be raised in order for the Company to accept subscriptions received from investors and the Company’s may terminate this Offering prior to the expiration of the Offering Period. There is no assurance that the Company will sell a sufficient number of Units in this Offering on a timely basis or that the net proceeds after payment of debts and other obligations will be adequate for the Company’s needs.
 (d)
 Need for Additional Capital; Additional Private Placement.  The net proceeds raised by the Company from this Offering will be used immediately to fund the Company’s current operations. The Company will therefore require significant additional financing shortly after this Offering, regardless of the net proceeds received, in order to satisfy its cash requirements. Upon completion of this offering, the Company intends to affect a registration on Form S-1, become a publicly traded entity and seek to raise additional funds in private placement transactions. However, there is no assurance that it will be able to do so in a timely manner or on terms that will enable it to enter its proposed business on a reasonable basis. 
 

 

 

 
 

 

 (e)
 Restrictions on Resale.  The Units and the Shares, are “restricted” securities and may not be resold or otherwise transferred except pursuant to an effective registration statement or an exemption under the 1933 Act and applicable state or “blue sky” laws.
 (f)
 Planned Expansion.  While the Company has operated since July 2003, we intend to expand our operations and hire additional personnel. In connection with our expansion, we may experience the following:
                                        -  lack of sufficient capital:
                                        -  competition
                                        -  adverse effects of general economic conditions;
 
                                       -  uncertain market acceptance of our services;
 
                                       -  an intense and immediate need for additional personnel.
 

 (g)
 Dependence upon the Company’s Sole Officer and Director. The Company is wholly dependent upon Nazneen D’Silva, currently the sole officer and director of the Company, for the operations and success of the Company.  The loss of her services would have a material adverse effect on the Company’s business, financial condition and results of operations.  The Company does not have an employment agreement with Nazneen D’Silva.
 (h)
 Capital Structure of the Company.  The following sets forth the capital structure of the Company prior to the sale of any Securities in this Offering.
 (i)
 The Company has one hundred five million (105,000,000) authorized shares of capital stock consisting of (A) one hundred million (100,000,000) shares of Common Stock and five million (5,000,000) shares of blank check preferred stock.
 (ii)
 The Company has 10,200,000 shares of Common Stock issued and outstanding as follows:
 (A)
 Nazneen D’Silva – 10,000,000; and
 

 (B)
 Frank J. Hariton – 200,000 Shares.
 

 Mrs. D’Silva may reallocate a portion of her shares in the future.
 

 (iii)
 The Company has no other securities currently issued and outstanding and there are no warrants, options or other securities outstanding that are convertible into or exercisable for any securities of the Company.
 

 

 

 

 
 

 

 1.6
 Summary of Proposed Business.  The Company operates a coffee shop which it intends to expand.  The Company will secure additional space, hire necessary personnel and seek to further expand its business. Based on management’s assessment of the Company’s operating history, the Company believes that it represents a legitimate business to its potential shareholders. 
 

 1.7
 Information.  The Subscriber acknowledges receipt and full and careful review and understanding of this Subscription Agreement with any exhibits thereto (the “Offering Document”) and hereby represents that: (i) it has been furnished by the Company during the course of this transaction with all information regarding the Company which it has requested; and (ii) that it has been afforded the opportunity to ask questions of and receive answers from duly authorized officers of the Company concerning the terms and conditions of the Offering, and any additional information which it has requested.
 1.8
 No Representations or Warranties.  The Subscriber hereby represents that, except as expressly set forth in the Offering Document, no representations or warranties have been made to the Subscriber by the Company or any agent, employee or affiliate of the Company and in entering into this transaction the Subscriber is not relying on any information other than that contained in the Offering Documents and the results of independent investigation by the Subscriber.
 1.9
 Tax Consequences. The Subscriber acknowledges that this Offering of the Units may involve tax consequences and that the contents of the Offering Documents do not contain tax advice or information. The Subscriber acknowledges that it must retain its own professional advisors to evaluate the tax and other consequences of an investment in the Units.
 1.10
 Transfer or Resale. The Subscriber understands that: (a) none of the Securities have been and are not being registered under the 1933 Act or any state securities laws; (b) the Securities may not be offered for sale, sold, assigned, pledged, transferred or otherwise disposed of (each a “Disposition”) unless, prior to effecting any such Disposition (other than any transfer not involving a change in beneficial ownership) (i) there is in effect a registration statement under the 1933 Act covering the Disposition and the Disposition is made in accordance with such registration statement, or (ii) the Subscriber gives written notice to the Company of such Subscriber’s intention to effect a Disposition and such notice shall describe the manner and circumstances of the proposed Disposition, and shall be accompanied by either (A) a written opinion of a legal counsel that a Disposition of the Securities may be made pursuant to an exemption from such registration, or (B) any other evidence reasonably satisfactory to counsel to the Company; and (C) the Company is under no obligation to register the Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any registration exemption thereunder.
 1.11
 Legends. The Subscriber understands that the certificates or other instruments representing the Securities, until such time as they have been registered under the 1933 Act as contemplated by the Registration Rights Agreement, shall bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of such certificates or other instruments):
 

 

 

 
 

 

 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, OR (B) AN OPINION OF COUNSEL, IN A REASONABLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS. 
 The legend set forth above shall be removed and the Company shall issue a certificate or other instrument without such legend to the holder of the Securities upon which it is stamped, if (a) there is in effect a registration statement under the 1933 Act covering the Disposition and the Disposition is made in accordance with such registration statement or (b) if the Disposition of the Securities is completed in satisfaction of the requirements of Rule 144 of the 1933 Act.
 1.12
 Validity; Enforcement.  If the Subscriber is a corporation, partnership, trust or other entity, the Subscriber represents and warrants that: (a) it is authorized and otherwise duly qualified to purchase and hold the Units; and (b) that this Subscription Agreement has been duly and validly authorized, executed and delivered and constitutes the legal, binding and enforceable obligation of the undersigned.
 1.13
 Residency. The Subscriber represents that its principal address is furnished at the end of this Subscription Agreement.
 1.14
 Foreign Subscriber. If the Subscriber is not a United States person, such Subscriber hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Units or any use of this Subscription Agreement, including: (a) the legal requirements within its jurisdiction for the purchase of the Units; (b) any foreign exchange restrictions applicable to such purchase; (c) any governmental or other consents that may need to be obtained; and (d) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the securities comprising the Units. Such Subscriber’s subscription and payment for, and his or her continued beneficial ownership of the Units, will not violate any applicable securities or other laws of the Subscriber’s jurisdiction.
 1.15
 NASD Member. The Subscriber acknowledges that if it is a Registered Representative of an NASD member firm, the Subscriber must give such firm notice required by the NASD’s Rules of Fair Practice, receipt of which must be acknowledged by such firm on the signature page hereof.
 1.16
 Confidential Information.  The subscriber acknowledges that the information contained in this Subscription Agreement and the related schedules and Exhibits, as well as any other information relating to the Company that has been provided to the Subscriber in connection with this Offering is the confidential and proprietary information of the Company.  The Subscriber agrees that he shall not disclose any of said information to any other person, 
 

 

 

 
 

 

 except for his financial and legal advisors, who require such information to advise the Subscriber with respect to his contemplated investment, and in the event that the Subscriber does not invest in this Offering, he shall return all materials provided to him by the Company, including any copies thereof, to the Company.
 

 II.
 REPRESENTATIONS BY THE COMPANY
 The Company represents and warrants to the Subscriber, except as set forth in the disclosure schedules attached hereto:
 2.1
 Organization and Qualification. The Company and its “Subsidiaries” (which for purposes of this Subscription Agreement means any entity in which the Company, directly or indirectly, owns capital stock and holds a majority or similar interest) are duly organized and validly existing in good standing under the laws of the jurisdiction in which they were organized, and have the requisite power and authorization to own their properties and to carry on their business as now being conducted. Each of the Company and its Subsidiaries is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used in this Subscription Agreement, “Material Adverse Effect” means any material adverse effect on the business, properties, assets, operations, results of operations or financial condition of the Company and its Subsidiaries, if any, taken as a whole, or on the transactions contemplated hereby, or by the other Offering Documents or the agreements and instruments to be entered into in connection herewith or therewith, or on the authority or ability of the Company to perform its obligations under the Offering Documents. 
 2.2
 Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its obligations under this Subscription Agreement and the Escrow Agreement and to perform its obligations under the Offering Document, and to issue the Securities in accordance with the terms of the Offering Document. The execution and delivery of the Offering Document by the Company and the consummation by the Company of the transactions contemplated by the Offering Documents, including without limitation the issuance of the Securities, have been duly authorized by the Company’s board of directors and no further consent or authorization is required by the Company, its board of directors or its stockholders. The Offering Documents have been duly executed and delivered by the Company, and constitute valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.
 2.3
 Capitalization. Prior to the Initial Closing, the authorized, issued and outstanding securities of the Company (including, but not limited to, all and/or other securities convertible into equity securities of the Company and all options and warrants, all of which are listed in 
 

 

 

 
 

 

 Section 1.1(i) of this Subscription Agreement.  All of the issued and outstanding securities of the Company have been and are, or upon issuance will be duly authorized, validly issued, fully paid and non-assessable. Except as disclosed in Offering Document, (i) no shares of the Company's capital stock are subject to preemptive rights under Delaware law or any other similar rights or any liens or encumbrances suffered or permitted by the Company; (ii) there are no outstanding debt securities issued by the Company; (iii) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exchangeable for, any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exchangeable for, any shares of capital stock of the Company or any of its Subsidiaries; (iv) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act; (v) there are no outstanding securities of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries; (vi) there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities as described in the Offering Documents; and (vii) the Company does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement. All prior sales of securities of the Company were either registered under the 1933 Act and applicable state securities laws or exempt from such registration, and no security holder has any rescission rights with respect thereto.
 2.4
 Issuance of Securities; Reservation. The issuance, sale and delivery of the Securities have been duly authorized by all requisite corporate action by the Company and, upon issuance in accordance with the Offering Documents, shall be (a) duly authorized, validly issued, fully paid and non-assessable, (b) free from all taxes, liens and charges with respect to the issue thereof except that may be created by the Subscriber, and (c) entitled to the rights and preferences set forth in the Securities. Assuming (i) the accuracy of the information provided by the respective Subscribers in the Subscription Agreement and Questionnaire, and (ii) that all of the offerees and Subscribers are “accredited investors” as such term is defined in Rule 501 of Regulation D, the offer and sale of the Units pursuant to the terms of this Subscription Agreement are and will be exempt from the registration requirements of the 1933 Act and the rules and regulations promulgated thereunder. The Company is not disqualified from the exemption under Regulation D by virtue of the disqualification contained in Rule 507 thereof or otherwise.
 2.5
 No Conflicts. Except as set forth in the Offering Documents, the execution, delivery and performance of the Offering Documents by the Company, the consummation by the Company of the transactions contemplated by the Offering Documents, and the issuance of the Securities and performance by the Company of its obligations under the Offering Documents, will not (a) result in a violation of the Company’s Certificate of Incorporation, any other 
 

 

 

 
 

 

 certificate of designations, preferences and rights of any outstanding series of preferred stock of the Company, or the Company’s By-Laws, (b) conflict with, or constitute a default or an event which with notice or lapse of time or both would become a default under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material agreement, note and/or other indebtedness, lease, license or instrument, or (c) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and the rules and regulations of the NASD) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected.
 2.6
 Consents. The Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations under or contemplated by the Offering Documents. Except as otherwise provided in the Offering Documents, all consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof. The Company and its Subsidiaries are unaware of any facts or circumstances which might prevent the Company from obtaining or effecting any of the foregoing.
 2.7
 No General Solicitation. None of the Company, its Subsidiaries, any of their affiliates, and any person acting on their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the 1933 Act) in connection with the offer or sale of the Securities.
 2.8
 No Integrated Offering. None of the Company, its Subsidiaries, any of their affiliates, and any person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of any of the Securities under the 1933 Act by causing this Offering of the Securities to be integrated with prior offerings by the Company for purposes of the 1933 Act or any applicable stockholder approval provisions, including without limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of the Company are listed or designated, or otherwise. None of the Company, its Subsidiaries, their affiliates and any person acting on their behalf will take any action or steps referred to in the preceding sentence that would require registration of any of the Securities under the 1933 Act by causing the Offering of the Securities to be integrated with other offerings, or otherwise.
 2.9
 Foreign Corrupt Practices. Neither the Company, nor any of its Subsidiaries, nor any director, officer, agent, employee or other person acting on behalf of the Company or any of its Subsidiaries has, in the course of its actions for, or on behalf of, the Company, (a) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds, (b) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or (c) made any 
 

 

 

 
 

 

 unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.
 2.10
  Absence of Litigation. Except as set forth in the Offering Document, there is no action, suit, proceeding, inquiry or investigation before or by the NASD, any court, public board, government agency, self-regulatory organization or body, or arbitrator pending or, to the knowledge of the Company, threatened against the Company, the Common Stock or any of the Company’s Subsidiaries or any of the Company’s or the Company’s Subsidiaries’ officers or directors in their capacities as such.
 2.11
 Tax Status. Except as set forth in the Offering Document, the Company and each of its Subsidiaries has made or filed all federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, except when the failure to do so would not have a Material Adverse Effect, and has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations or to the Company’s knowledge otherwise due and payable, except those being contested in good faith and has set aside on its books reserves in accordance with GAAP reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.
 2.12
 Securities Law Compliance. The offer, offer for sale, and sale of the Units has not been registered with the SEC. The Units are to be offered, offered for sale and sold in reliance upon the exemptions from the registration requirements of Section 5 of the 1933 Act. The Company will conduct the Offering in compliance with the requirements of Regulation D under the 1933 Act, and the Company will file all appropriate notices of offering with the SEC.
 2.13
 Title. Except as set forth in or contemplated by the Offering Document, the Company has good and marketable title to all material properties and tangible assets owned by it, free and clear of all liens, charges, encumbrances or restrictions, except as such as are not significant or important in relation to the Company’s business; all of the material leases and subleases under which the Company is the lessor or sublessor of properties or assets or under which the Company holds properties or assets as lessee or sublessee are in full force and effect, and the Company is not in default in any material respect with respect to any of the terms or provisions of any of such leases or subleases, and to the Company’s knowledge no material claim has been asserted by anyone adverse to rights of the Company as lessor, sublessor, lessee or sublessee under any of the leases or subleases mentioned above, or affecting or questioning the right of the Company to continued possession of the leased or subleased premises or assets under any such lease or sublease. The Company owns, leases or licenses all such properties as are necessary to its operations as described in the Offering Documents.
 2.14
 Intellectual Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, 
 

 

 

 
 

 

 governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted, the lack of which could reasonably be expected to have a Material Adverse Effect. Except as set forth in the Offering Documents, to the Company’s knowledge, none of the Company's trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property rights have expired or terminated, or are expected to expire or terminate within two (2) years from the date of this Subscription Agreement, except where such expiration or termination would not have either individually or in the aggregate a Material Adverse Effect. The Company and its Subsidiaries do not have any knowledge of any infringement by the Company or its Subsidiaries of trademarks, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks, service mark registrations, trade secrets or other similar rights of others, or of any such development of similar or identical trade secrets or technical information by others and, except as set forth in the Offering Document, no claim, action or proceeding has been made or brought against, or to the Company's knowledge, has been threatened against, the Company or its Subsidiaries regarding trademarks, trade name rights, patents, patent rights, inventions, copyrights, licenses, service names, service marks, service mark registrations, trade secrets or other infringement, except where such infringement, claim, action or proceeding would not reasonably be expected to have either individually or in the aggregate a Material Adverse Effect. Except as set forth in the Offering Document, the Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties except where the failure to do so would not have either individually or in the aggregate a Material Adverse Effect.
 2.15
 Registration Rights. Except as set forth in the Offering Document, no person has any right to cause the Company to effect the registration under the 1933 Act of any securities of the Company.
 2.16
 Brokers. Neither the Company nor any of its officers, directors, employees or stockholders has employed any broker or finder in connection with the transactions contemplated herein.
 2.17
 Disclosure. None of the representations and warranties of the Company appearing in this Subscription Agreement or any information appearing in any Exhibit or Schedule hereto other than material which says it is a “belief” or “expectation” of the Company or similarly qualified, which statements the Company believes to the best of its knowledge as of the date hereof and at each Closing Date to be true and accurate in all material respects and not misleading), when considered together as a whole, contains, or on any Closing Date will contain, any untrue statement of a material fact or omits, or on any Closing Date will omit, to state any material fact required to be stated herein or therein in order for the statements herein or therein, in light of the circumstances under which they were made, not to be misleading.
 

 

 

 

 
 

 

 III.
 TERMS OF SUBSCRIPTION
 3.1
 Closing and Termination of Offering.  Provided that the required conditions to closing set forth in Article V and Article VI hereof have been satisfied or waived, a closing (the “Initial Closing”) shall take place at the offices of the Company as set forth herein or at such place as may otherwise be agreed to by the Company within 30 days of the receipt of the first cleared subscriber’s funds.  The Company may consummate subsequent closings of the Offering, upon mutual agreement only, each of which shall be subject to satisfaction or waiver of the conditions to closing set forth in Article V and Article VI hereof, and each of which shall be deemed a “Closing” hereunder. The date of the last closing of the Offering is hereinafter referred to as the “Final Closing” and the date of any Closing hereunder is hereinafter referred to as a “Closing Date.” The offering period for the Offering shall commence on the day the Offering Document is first delivered to prospective Subscribers by the Company for delivery in connection with the offering for sale of the Units and shall continue until the earlier to occur of: (i) the sale of the all of the Units being offered pursuant to this Offering; and (ii) 5:00 p.m. (New York City Time), March 31, 2012; provided, however, that (A) if all of the Units have not been sold on or prior to March 31, 2012, this Offering may be extended for an additional ninety (90) days by the Company in its sole discretion and (B) this Offering may be terminated prior to March 31, 2012, upon the sole action of the Company. The day that the Offering Period terminates is hereinafter referred to as the “Termination Date.”
 3.2
 Certificates. The Subscriber hereby authorizes and directs the Company, upon each closing of the Offering, to (i) deliver the certificates representing the Shares (the “Stock Certificates”) to be issued to such Subscriber pursuant to this Subscription Agreement to the Subscriber’s address indicated in the Questionnaire, by thirty (30) days after the applicable Closing Date.
 IV.
 COVENANTS
 

 4.1
 Form D and Blue Sky. The Company shall file a Form D with respect to the Units as required under Regulation D under the 1933 Act and, upon written request, provide a copy thereof to the Subscriber promptly after such filing. The Company shall, on or before the Closing, take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Units for sale to the Subscriber pursuant to this Subscription Agreement under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of any such action so taken to the Subscriber on or prior to the Closing. The Company shall make all filings and reports relating to the offer and sale of the Securities required under applicable securities or “Blue Sky” laws of the states of the United States following the Closing.
 4.2
 Use of Proceeds. The Company shall only use the net proceeds from the sale of the Units for the following purposes:
 (a)
 To pay the expenses of the Offering, including, but not limited to legal and accounting fees;
 

 

 

 
 

 

 (b)
 To fund the costs of a Securities Act Registration Statement; and
 (c)
 Working capital requirements.
 

 V.
 CONDITIONS TO CLOSING IN FAVOR OF THE COMPANY
 

 The obligation of the Company hereunder to issue and sell Units to the Subscriber at the Closing is subject to the satisfaction, at or before the Closing, of each of the following conditions, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing the Subscriber with prior written notice thereof:
 5.1
 Offering Documents. The Subscriber shall have executed a Questionnaire, a Subscription Agreement and delivered the same to the Company.
 5.2
 Purchase Price. The Subscriber shall have paid the purchase price for the Units being purchased by the Subscriber at the Closing in the manner set forth in Section 1.1.
 5.3
 Representations and Warranties. The representations and warranties of the Subscriber shall be true and correct in all material respects as of the date when made and as of the Closing as though made at that time, and the Subscriber shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied or complied with by the Subscriber at or prior to the Closing.
 5.4
 Other Matters. All opinions, certificates and documents and all proceedings related to this Offering shall be in form and content reasonably satisfactory to the Company and its legal counsel.
 VI.
 CONDITIONS TO CLOSING IN FAVOR OF THE SUBSCRIBER
 The obligation of the Subscriber hereunder to purchase the Units is subject to the satisfaction, at or before the Closing, of each of the following conditions, provided that these conditions are for the Subscriber’s sole benefit and may be waived by the Subscriber at any time in its sole discretion by providing the Company with prior written notice thereof:
 6.1
 Offering Documents. The Company shall have executed and delivered to the Subscriber each of the Offering Documents to which its signature is required.
 6.2
 Representations and Warranties. The representations and warranties of the Company shall be true and correct as of the date when made and as of the Closing as though made at that time (except for representations and warranties that reference a specific date which shall have been true and correct in all material respects as of such date), and the Company shall have performed, satisfied and complied in all respects with the covenants, agreements and conditions required by the Offering Documents to be performed, satisfied or complied with by the Company at or prior to the Closing.
 

 

 

 
 

 

 VII.
 RIGHTS OF TERMINATION
 7.1
 Termination by Subscriber or Company. This Subscription Agreement may be terminated at any time prior to the Closing: (a) by mutual written consent of the parties hereto; or (b) by the Company or the Subscriber upon written notice to the other party if any court or governmental authority of competent jurisdiction shall have issued a final, non-appealable order restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated by this Subscription Agreement. Termination of this Subscription Agreement under this Section 7.1 shall result in this Subscription Agreement becoming void and of no further force and effect, except that a termination shall not release, or be construed as so releasing, any party hereto from any liability or damage to the other party hereto arising out of the breaching party’s willful and material breach of the warranties and representations made by it, or willful and material failure in performance of any of its covenants, agreements, duties or obligations provided hereunder, and the obligations under Section 8.8 shall survive such termination.
 

 VIII.
 MISCELLANEOUS
 

 8.1
 Notice. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Subscription Agreement must be in writing and will be deemed to have been delivered: (a) upon receipt, when delivered personally, (b) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party), or (c) one (1) business day after deposit with an overnight courier service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications shall be:
 

 If to the Company at the address set forth in the first paragraph of this agreement, Attn. Nazneen D’Silva President and CEO. 
 

 If to the Subscriber, to its address and facsimile number set forth at the end of this Subscription Agreement, or to such other address and/or facsimile number and/or to the attention of such other person as specified by written notice given to the Company five (5) days prior to the effectiveness of such change.
 Written confirmation of receipt (a) given by the recipient of such notice, consent, waiver or other communication, (b) mechanically or electronically generated by the sender’s facsimile machine containing the time, date, recipient facsimile number and an image of the first page of such transmission, or (c) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clauses (a), (b) or (c) above, respectively.
 8.2
 Entire Agreement; Amendment. This Subscription Agreement supersedes all other prior oral or written agreements between the Subscriber, the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Subscription 
 

 

 

 
 

 

 Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Subscriber makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Subscription Agreement may be amended or waived other than by an instrument in writing signed by the Company and each Noteholder.
 8.3
 Severability. If any provision of this Subscription Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Subscription Agreement in that jurisdiction or the validity or enforceability of any provision of this Subscription Agreement in any other jurisdiction.
 8.4
 Governing Law; Jurisdiction. This Agreement shall be governed by and construed solely in accordance with the internal laws of the State of Texas with respect to contracts executed, delivered and to be fully performed therein, without regard to the conflicts of laws principles thereof. The parties hereto hereby expressly and irrevocably agree that any suit or proceeding arising under this Agreement or the consummation of the transactions contemplated hereby, shall be brought solely in a federal or state court located in the City and County of Houston, State of Texas. By its execution hereof, Company and Subscriber hereby expressly and irrevocably submits to the in personam jurisdiction of the federal and state courts located in the City, County and State of Texas and agree that any process in any such action may be served upon him or her personally, or by certified mail or registered mail upon such party or such agent, return receipt requested, with the same full force and effect as if personally served upon such party in Houston, Texas. The parties hereto each waive any claim that any such jurisdiction is not a convenient forum for any such suit or proceeding and any defense or lack of in personam jurisdiction with respect thereto. In the event of any such action or proceeding, the party prevailing therein shall be entitled to payment from the other party hereto of its reasonable counsel fees and disbursements.
 8.5
 Headings. The headings of this Subscription Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Subscription Agreement.
 8.6
 Successors And Assigns. This Subscription Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns, including any purchasers of the Units. The Company shall not assign this Subscription Agreement or any rights or obligations hereunder. Subscriber may assign some or all of its rights hereunder without the consent of the Company, provided, however, that any such assignment shall not release the Subscriber from its obligations hereunder unless such obligations are assumed by such assignee and the Company has consented to such assignment and assumption, which consent shall not be unreasonably withheld.
 8.7
 No Third Party Beneficiaries. This Subscription Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.
 

 

 

 
 

 

 8.8
 Survival. The representations and warranties of the Company and the Subscriber contained in Article I and Article II and the agreements set forth this Article VIII shall survive the Closing for a period of twelve (12) months.
 8.9
 Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Subscription Agreement and the consummation of the transactions contemplated hereby.
 8.10
 No Strict Construction. The language used in this Subscription Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.
 8.11
 Legal Representation. The Subscriber acknowledges that: (a) it has read this Subscription Agreement and the exhibits hereto; (b) it understands that the Company has been represented in the preparation, negotiation, and execution of this Subscription Agreement by Frank Hariton, Esq., counsel to the Company; (c) it has either been represented in the preparation, negotiation, and execution of this Subscription Agreement by legal counsel of its own choice, or has chosen to forego such representation by legal counsel after being advised to seek such legal representation; and (d) it understands the terms and consequences of this Subscription Agreement and is fully aware of its legal and binding effect.
 8.12
 Confidentiality. The Subscriber agrees that it shall keep confidential and not divulge, furnish or make accessible to anyone, the confidential information concerning or relating to the business or financial affairs of the Company contained in the Offering Documents to which it has become privy by reason of this Subscription Agreement.
 8.13
 Counterparts. This Subscription Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile signature.
 

 

 

 

 

 

 

 Remainder of Page Intentionally Left Blank
 

 

 

 
 

 

 

 IN WITNESS WHEREOF, the parties have executed this Subscription Agreement as of the date first written above.
 

 	 	 	 	
	 SUBSCRIBER **
	  
	 CO-SUBSCRIBER **

	  
	  
	  

	 Signature of Subscriber
	  
	 Signature of Co-Subscriber

	  
	  
	  

	 Name of Subscriber [please print]
	  
	 Name of Co-Subscriber [please print]

	  
	  
	  

	 Address of Subscriber
	  
	 Address of Co-Subscriber

	  
	  
	  

	 Social Security or Taxpayer
 Identification Number of Subscriber
	  
	 Social Security or Taxpayer Identification
 Number of Co-Subscriber

	 

 Name of Holder(s) as it should appear on the security certificates* [please print]
	  

 

 * Please provide the exact names that you wish to see on the certificates
 

 (1)
 For individuals, print full name of subscriber.
 (2)
 For joint, print full name of subscriber and all co-subscribers.
 (3)
 For corporations, partnerships, LLC, print full name of entity, including “&,” “Co.,” “Inc.,” “etc,” “LLC,” “LP,”etc.
 (4)
 For Trusts, print trust name (please contact your trustee for the exact name that should appear on the certificates.)
 

 

 Dollar Amount of Units Subscribed For: $__________________
 

 Dollar Amount of Units
 Subscription Accepted: $_________________
 

 SUBSCRIPTION ACCEPTED BY THE COMPANY
 

 KOFFEE KORNER INC. 
 

 

 By:___________________________________
 Nazneen D’Silva, President & CEO
 

 **If Subscriber is a Registered Representative with an NASD member firm or an affiliated person of an NASD member firm, have the acknowledgment to the right signed by the appropriate party:
 

 The undersigned NASD Member firm acknowledges receipt of the notice required by Rule 3040 of the NASD Conduct Rules.
 

 Name of NASD Member Firm
 

 By:____________________________
 Authorized Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]